PE20060997A1 - PHARMACEUTICAL FORMULATION AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF BENZISOXAZOLE DERIVATIVES - Google Patents

PHARMACEUTICAL FORMULATION AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF BENZISOXAZOLE DERIVATIVES

Info

Publication number
PE20060997A1
PE20060997A1 PE2006000132A PE2006000132A PE20060997A1 PE 20060997 A1 PE20060997 A1 PE 20060997A1 PE 2006000132 A PE2006000132 A PE 2006000132A PE 2006000132 A PE2006000132 A PE 2006000132A PE 20060997 A1 PE20060997 A1 PE 20060997A1
Authority
PE
Peru
Prior art keywords
equal
less
benzisoxazole
side effects
reduce
Prior art date
Application number
PE2006000132A
Other languages
Spanish (es)
Inventor
Gayatri Sathyan
Suneel Gupta
Iran Reyes
Atul D Ayer
Sonya Seroff
Julie Lee
Nipun Davar
Noymi V Yam
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/051,060 external-priority patent/US20050208132A1/en
Application filed by Alza Corp filed Critical Alza Corp
Publication of PE20060997A1 publication Critical patent/PE20060997A1/en

Links

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UNA DOSIS D DE UN DERIVADO DE BENZISOXAZOL TAL COMO RISPERIDONA, PALIPERIDONA Y METABOLITOS ACTIVOS PARA USO FARMACEUTICO. DICHA COMPOSICION, DE LIBERACION PROLONGADA, PROPORCIONA: A) UNA CONCENTRACION MAXIMA DE PLASMA, DE LA MEDIA, DE DOSIS SIMPLE DEL DERIVADO DE BENZISOXAZOL Y METABOLITOS ACTIVOS CARACTERIZADA POR LA RELACION 0,5 ng/ml/mg MENOR O IGUAL Cmax/D MENOR O IGUAL 8 ng/ml/mg; B)UN AREA DE DOSIS SIMPLE, DE LA MEDIA DE UNA CURVA DE TIEMPO DE CONCENTRACION DE PLASMA PARA AUCinf DEL DERIVADO DE BENZISOXAZOL Y METABOLITOS ACTIVOS CARACTERIZADA POR 30 ng hr/ml/mg MENOR O IGUAL AUCinf/D MENOR O IGUAL 300 ng hr/ml/mg. LA COMPOSICION FARMACEUTICA, DE ACUERDO A LAS CARACTERISTICAS MENCIONADAS, REDUCEN O ELIMINAN CIERTOS EFECTOS SECUNDARIOS DE RISPERIDONA Y SU METABOLITO PALIPERIDONA, EN EL TRATAMIENTO DE TRASTORNOS PSICOTICOSREFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING A DOSE DOSE OF A BENZISOXAZOLE DERIVATIVE SUCH AS RISPERIDONE, PALIPERIDONE AND ACTIVE METABOLITES FOR PHARMACEUTICAL USE. SUCH COMPOSITION, OF PROLONGED RELEASE, PROVIDES: A) A MAXIMUM CONCENTRATION OF PLASMA, OF THE AVERAGE, SINGLE DOSE OF THE DERIVATIVE OF BENZISOXAZOLE AND ACTIVE METABOLITES CHARACTERIZED BY THE RATIO 0.5 ng / ml / mg LESS OR EQUAL Cmax / D LESS OR EQUAL 8 ng / ml / mg; B) A SIMPLE DOSE AREA OF A MEAN OF A PLASMA CONCENTRATION TIME CURVE FOR AUCinf OF THE DERIVATIVE OF BENZISOXAZOLE AND ACTIVE METABOLITES CHARACTERIZED BY 30 ng hr / ml / mg LESS OR EQUAL AUCinf / D LESS OR EQUAL 300 ng hr / ml / mg. THE PHARMACEUTICAL COMPOSITION, ACCORDING TO THE MENTIONED CHARACTERISTICS, REDUCE OR ELIMINATE CERTAIN SIDE EFFECTS OF RISPERIDONE AND ITS METABOLITE PALIPERIDONE, IN THE TREATMENT OF PSYCHOTIC DISORDERS

PE2006000132A 2005-02-04 2006-02-02 PHARMACEUTICAL FORMULATION AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF BENZISOXAZOLE DERIVATIVES PE20060997A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/051,060 US20050208132A1 (en) 2002-07-29 2005-02-04 Methods and dosage forms for reducing side effects of benzisozazole derivatives

Publications (1)

Publication Number Publication Date
PE20060997A1 true PE20060997A1 (en) 2006-10-11

Family

ID=38048170

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000132A PE20060997A1 (en) 2005-02-04 2006-02-02 PHARMACEUTICAL FORMULATION AND DOSAGE FORMS TO REDUCE THE SIDE EFFECTS OF BENZISOXAZOLE DERIVATIVES

Country Status (4)

Country Link
AR (1) AR053671A1 (en)
PE (1) PE20060997A1 (en)
TW (1) TW200638936A (en)
UY (1) UY29363A1 (en)

Also Published As

Publication number Publication date
AR053671A1 (en) 2007-05-16
TW200638936A (en) 2006-11-16
UY29363A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
PE20190390A1 (en) CRYSTALLINE FORMS OF A BRUTON TYROSINE KINASE INHIBITOR
CL2017003445A1 (en) Solid forms and formulations of imidazopyrazine compounds.
NI201000003A (en) TRISUSTITUED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES.
AR108594A2 (en) PHARMACEUTICAL FORMULATIONS THAT KEEP FLAVOR WITH IMPROVED PHARMACEUTICAL CHARACTERISTICS
AR061771A1 (en) THERAPEUTIC ADMINISTRATION SYSTEM
UY29701A1 (en) LIQUID FORMULATIONS FOR THE CONTROLLED ADMINISTRATION OF BENCISOXAZOL DERIVATIVES
ECSP088974A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHEOSE QUINASA GLYCOGEN (GSK3)
AR084691A1 (en) TOPICAL USE FORMULATION FOR A JAK INHIBITOR AND METHOD TO TREAT SKIN DISORDER
PE20180203A1 (en) PROCEDURE FOR THE PREPARATION OF {4,6-DIAMINE-2- [1- (2-FLUOROBENZYL) -1H-PIRAZOLO [3,4-B] PYRIDIN-3-IL] PYRIMIDIN-5-IL} METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE
ECSP088973A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHETIC KINASE GLYCOGEN (GSK3)
AR061166A1 (en) PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF PHENYLPHERINE
PE20211818A1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION INCLUDING A DERIVATIVE OF AMINOPYRIMIDINE OR ITS SALT
CL2021003034A1 (en) Methods of treatment of sjögren's syndrome using a bruton's tyrosine kinase inhibitor
CO2022017622A2 (en) nek7 kinase inhibitors
CL2010000524A1 (en) Use of a topical composition comprising 3.75% imiquimod and a pharmaceutically acceptable carrier to prepare a medicament useful for treating genital or perianal warts.
AR047469A1 (en) ANTIMICROBIAL PRESERVANTS TO ACHIEVE A MULTIPLE DOSE FORMULATION USING BETA CYCLODEXTRINES FOR LIQUID DOSAGE FORMS
AR064543A1 (en) USE OF DIANHYDROHEXITE MONONITRATE DERIVATIVES AS AGENTS FOR THE TREATMENT OF INTESTINAL DISORDERS
CO2022019131A2 (en) nek7 kinase inhibitors
MX2023003758A (en) Pharmaceutical formulations.
CR10210A (en) BENZOISOINDOL DERIVATIVES FOR PAIN TREATMENT
ES2616882T3 (en) Pharmaceutical composition comprising an adenosine A3 receptor agonist (IB-MECA / CF-101) for the treatment of psoriasis
UY29561A1 (en) DERIVATIVES OF QUINAZOLINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS
AR075866A1 (en) A DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL DETERIORATION. USE. PHARMACEUTICAL COMPOSITION
AR059225A1 (en) CITRATE SALT, PREPARATION PROCESS AND ITS ACTIVITY IN THERAPY
ES2526359T3 (en) Oral galenic formulation comprising ketorolac and B vitamins, in which vitamin B6 is in an external layer separated from the rest of active ingredients

Legal Events

Date Code Title Description
FC Refusal